Geodesic
Widespread Immunity to Breast and Prostate Cancers is Predicted by a Novel Model that also Determines Sporadic and Hereditary Susceptible Population Sizes
I. Kramer1
1 Physics Department, University of Maryland Baltimore County
Mathematical modelling of natural phenomena, Tome 5 (2010) no. 3, pp. 134-164.

Voir la notice de l'article provenant de la source EDP Sciences

Natural immunity to breast and prostate cancers is predicted by a novel, saturated ordered mutation model fitted to USA (SEER) incidence data, a prediction consistent with the latest ideas in immunosurveillance. For example, the prevalence of natural immunity to breast cancer in the white female risk population is predicted to be 76.5%; this immunity may be genetic and, therefore, inherited. The modeling also predicts that 6.9% of White Females are born with a mutation necessary to cause breast cancer (the hereditary form) and, therefore, are at the highest risk of developing it. By contrast, 16.6% of White Females are born without any such mutation but are nonetheless susceptible to developing breast cancer (the sporadic form). The modeling determines the required number of ordered mutations for a cell to become cancerous as well as the mean time between consecutive mutations for both the sporadic and hereditary forms of the disease. The mean time between consecutive breast cancer mutations was found to vary between 2.59 - 2.97 years, suggesting that such mutations are rare events and establishing an upper bound on the lifetime of a breast cell. The prevalence of immunity to breast cancer is predicted to be 79.7% in Blacks, 86.5% in Asians, and 85.8% in Indians. Similarly, the prevalence of immunity to prostate cancer is predicted to be 67.4% for Whites, 50.5% for Blacks, 77.7% for Asians, and 78.6% for Indians. It is of paramount importance to delineate the mechanism underlying immunity to these cancers.
DOI : 10.1051/mmnp/20105309

I. Kramer 1

1 Physics Department, University of Maryland Baltimore County 
@article{MMNP_2010_5_3_a9,
     author = {I. Kramer},
     title = {Widespread {Immunity} to {Breast} and {Prostate} {Cancers} is {Predicted} by a {Novel} {Model} that also {Determines} {Sporadic} and {Hereditary} {Susceptible} {Population} {Sizes}},
     journal = {Mathematical modelling of natural phenomena},
     pages = {134--164},
     publisher = {mathdoc},
     volume = {5},
     number = {3},
     year = {2010},
     doi = {10.1051/mmnp/20105309},
     language = {en},
     url = {http://geodesic.mathdoc.fr/articles/10.1051/mmnp/20105309/}
}
TY  - JOUR
AU  - I. Kramer
TI  - Widespread Immunity to Breast and Prostate Cancers is Predicted by a Novel Model that also Determines Sporadic and Hereditary Susceptible Population Sizes
JO  - Mathematical modelling of natural phenomena
PY  - 2010
SP  - 134
EP  - 164
VL  - 5
IS  - 3
PB  - mathdoc
UR  - http://geodesic.mathdoc.fr/articles/10.1051/mmnp/20105309/
DO  - 10.1051/mmnp/20105309
LA  - en
ID  - MMNP_2010_5_3_a9
ER  - 
%0 Journal Article
%A I. Kramer
%T Widespread Immunity to Breast and Prostate Cancers is Predicted by a Novel Model that also Determines Sporadic and Hereditary Susceptible Population Sizes
%J Mathematical modelling of natural phenomena
%D 2010
%P 134-164
%V 5
%N 3
%I mathdoc
%U http://geodesic.mathdoc.fr/articles/10.1051/mmnp/20105309/
%R 10.1051/mmnp/20105309
%G en
%F MMNP_2010_5_3_a9
I. Kramer. Widespread Immunity to Breast and Prostate Cancers is Predicted by a Novel Model that also Determines Sporadic and Hereditary Susceptible Population Sizes. Mathematical modelling of natural phenomena, Tome 5 (2010) no. 3, pp. 134-164. doi : 10.1051/mmnp/20105309. http://geodesic.mathdoc.fr/articles/10.1051/mmnp/20105309/

[1] I. Kramer Evidence that natural immunity to breast cancer and prostate cancer exists in the majority of their risk populations is predicted by a novel, inherently saturated, ordered mutation model Computational and Mathematical Methods in Medicine 2008 1 26

[2] I. Kramer What triggers transient AIDS in the acute phase of HIV infection and chronic AIDS at the end of the incubation period?: A model analysis of HIV infection from the acute phase to chronic AIDS stage Computational and Mathematical Methods in Medicine 2007 125 151

[3] I. Kramer. Calculating the number of people with Alzheimer disease in any country using saturated mutation models of brain cell loss that also predict widespread natural immunity to the disease. Computational and Mathematical Methods in Medicine, Oct. 5, 2009.

[4] A. G. Knudson Mutation and cancer: statistical study of retinoblastoma Proc. Nat. Acad. Sci., USA 1971 820 823

[5] S. H. Friend, R. Bernards, S. Rogelj, R. A. Weinberg, J. M. Rapaport, D. M. Albert, T. P. Dryja A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma Nature 1986 643 646

[6] A. T. Yeung, B. B. Patel, X.-M. Li, S. H. Seeholzer, R. A. Coudry, H. S. Cooper, A. Bellacosa, B. M. Boman, T. Zhang, S. Litwin, E. A. Ross, P. Conrad, J. A. Crowell, L. Kopelovich, A. Knudson One-hit effects in cancer: altered proteome of morphologically normal colon crypts in familial adenomatous polyposis Cancer Research 2008 7579 7586

[7] S. Monfardini, E. Vaccher, G. Pizzocaro Unusual malignant tumors in 49 patients with HIV infection AIDS 1989 449 452

[8] S.C. Remick Non-AIDS-defining cancers Hematol Oncol Clin North Am. 1996 1203 1213

[9] C. Smith, S. Lilly, K.P. Mann AIDS-related malignancies Ann. Med. 1998 323 344

[10] T.P. Cooley Non-AIDS-defining cancer in HIV-infected people Hematol Oncol Clin North Am. 2003 889 899

[11] S.M. Mbulaiteye, R.J. Biggar, J.J. Goedert Immune deficiency and risk for malignancy among persons with AIDS J Acquir Immune Defic Syndr. 2003 527 533

[12] M. Frish, R.J. Biggar, E.A. Engels AIDS-Cancer Match Registry Study Group Association of cancer with AIDS-related immunosuppression in adults JAMA 2001 1736 1745

[13] F. Stephen Hodi, S. Granter, J. Antin Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report Cancer Immunity 2005

[14] N.F. Crum Increased risk of prostate cancer among HIV-infected men Contagion 2005 66 70

[15] W.G. Nelson, A.M. De Maizo, W.B. Issacs Mechanisms of disease: prostate cancer N Engl J Med 2003 366 381

[16] E.A. Platz, A.M. De Maizo Epidemiology of inflammation and prostate cancer J Urol 2004 S36 S40

[17] A.M. De Maizo, V.L. Marchi, J.L. Epstein Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis Am J Pathol 1999 1985 1992

[18] F. Steven Hodi, S. Granter, J. Antin Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report Cancer Immunity 2005

[19] J. Ruvinsky Are You Immune to Cancer?. DISCOVER 2006

[20] H. Davies Mutations of the BRAF gene in human cancer Nature 2002 949 54

[21] M.S. Brose, P. Volpe, M. Feldman, M. Kumar, I. Rishi BRAF and RAS mutations in human lung cancer and melanoma Cancer Res. 2002 6997 7000

[22] K.L. Novik, J.J. Spinelli, A.C. Macarthur, K. Shumansky, P. Sipahimalani, A. Lai, J.M. Conners, R.D. Gascovne, R.P. Gallagher, A.B. Brooks-Wilson Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma Cancer Epidemiol Biomarkers Prev 2007 1098 106

[23] H. Li, Y. Gu, B. Hukku, D.G. Mcleod, T.K. Hei, J.S. Rhim Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles Int J. Oncol. 2007 537 44

[24] P. Lichtenstein, N.V. Holm, P.K. Verkasalo, A. Iliadou, J. Kaprio, M. Koskenvuo, E. Pukkala, A. Skytthe, K. Hemminiki Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland N Engl J Med 2000 78 85

[25] R.K. Nam, W.W. Zhang, D.A. Loblaw, L.H. Klotz, J. Trachtenberg, M.A. Jewett, A. Stanimirovic, T.O. Davies, A. Toi, V. Venkateswaran, L. Sugar, K.A. Siminovitch, S.A. Naroid. A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporatic prostate cancer. Prostate Cancer Prostatic Dis., 2007 Sep 18, to be published.]

[26] A. Vecchione, F. Gottardo, L.G. Gomella, B. Wildemore, M. Fassan, E. Bragantini, F. Pagano, R. Baffa Molecular genetics of prostate cancer: clinical translational opportunities J Exp Clin Cancer Res 2007 25 37

[27] T.M. Lane, J.C. Strefford, R.J. Yanez-Munoz, P. Purkis, E. Forsythe, T. Nia, J. Hines, Y.L. Lu, R.T. Oliver Identification of a recurrent t(4 J Urol 2007 1907 12

[28] O. Saramaki, T. Visakorpi Chromal aberrations in prostate cancer Front Biosci 2007 3287 301

[29] I.M. Berguin, Y. Min, B. Wu, J. Wu, D. Perry, J.M. Cline, M.J. Thomas, T. Thornberg, G. Kulik, A. Smith, I.J. Edwards, R. Dõagnostino, H. Zhang, H. Wu, J.X. Kang, Y.Q. Chewn Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids J Clin Invest 2007 1866 75

[30] N. Yamamoto, M. Ueda. Therapeutic Efficacy of Vitamin D-binding Protein (Gc Protein)-derived Macrophage Activating Factor (GcMAF) for Prostate and Breast Cancers. 12th International Congress of immunology and 4th Annual Conference of FOCIS, Montreal, Canada, July 18-23, 2004.

[31] N. Yamamoto, H. Suyama, N. Yamamoto, N. Ushijima Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF) Int. J. Cancer 2008 461 467

[32] N. Yamamoto, H. Suyama, N. Yamamoto Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF Translational Oncology 2008 65 72

[33] N. Yamamoto Pathogenic significance of acetylgalactosaminidase Activity found in the Envelope Glycoprotein gp160 of Human Immunodeficiency Virus Type 1 AIDS Research and Human Retroviruses 2006 262 271

[34] N. Yamamoto, M. Ueda Pathogenic significance of acetylgalactosaminidase activity found in the hemagglutinin of influenza virus Microbes and Infection 2005 674 681

[35] N. Yamamoto, M. Ueda. Eradication of HIV by Treatment of HIV-infected/AIDS Patients with Vitamin D-binding Protein Derivative. 12th International Congress of immunology and 4th Annual Conference of FOCIS, Montreal, Canada, July 18-23, 2004.

[36] G.P. Dunn, L.J. Old, R.D. Schreiber The Immunobiology of Cancer Immunosurveillance and Immunoediting Immunity 2004 137 148

[37] G.P. Dunn, A.T. Bruce, H. Ikeda, L.J. Old, R.D. Schreiber Cancer immunoediting: from immunosurveillance to tumor escape Nature immunology 2002 991 998

[38] G.P. Dunn, C.M. Koebel, R.D. Schreiber Interferons, immunity, and cancer immunoediting Nat Rev Immunol. 2006 836 48

[39] Q. Zhihai, T. Blankenstein A cancer immunosurveillance controversy Nature Immunology 2004 3 4

[40] L. Zitvogel, A. Tesniere, G. Kroemer Cancer despite immunosurveillance: immunoselection and immunosubversion Nat Rev Immunol. 2006 715 27

[41] A.E. Germenis, V. Karanikas Immunoepigenetics: the unseen side of cancer immunoediting Immunol Cell Biol. 2007 55 9

[42] B.A. Inman, X. Frigola, H. Dong, E.D. Kwon Costimulation, coinhibition and cancer Curr Cancer Drug Targets 2007 15 30

[43] C. Greenman Patterns of somatic mutation in human cancer genomes Nature 2007 153 158

[44] P. Armitage, R. Doll The age distribution of cancer and a multi-stage theory of carcinogenesis British Journal of Cancer 1954 1 12

[45] F. Pompei, R. Wilson The age distribution of cancer Health and Environmental Risk Assessment 2001 1619 50

[46] P. Armitage, R. Doll A Two-Stage Theory of Carcinogenesis in Relation to the Age Distribution of Human Cancer Br. J. Cancer 1957 161 169

[47] S. Moolgavkar, A. Knudson 1981 Mutation and cancer: a model for human carcinogenesis J. Natl. Cancer Inst. 1037 1052

[48] S.H. Moolgavkar, A. Dewanji, D.J. Venzon 1988 A stochastic two-stage model for cancer risk assessment: I. The hazard function and the probability of tumor Risk Anal. 383 392

[49] S.H. Moolgavkar, E.G. Luebeck 1990 Two-event model for carcinogenesis: biological, mathematical, and statistical considerations Risk Anal. 323 341

[50] W.F. Heidenreich, E.G. Luebeck, S.H. Moolgavkar 1997 Some properties of the hazard function of the two-mutation clonal expansion model Risk Anal. 391 399

[51] E.G. Lueback, S.H. Moolgavkar Multistage carcinogenesis and the incidence of colorectal cancer PNA 2002 15095 15100

Cité par Sources :